Otezla vs Stelara: Psoriatic Arthritis Side effects, Cost, Dosage Review

Learn all about Otezla vs stelara psoriatic arthritis, side effects, cost, reviews, dosage. Psoriasis symptoms, psoriatic arthritis symptoms, Psoriasis types.

Psoriasis is one of the most commonly occurring disease across the globe. Psoriasis causes alteration in the normal cell cycle due to which cells proliferate very rapidly on the surface of skin.Excessive growth of skin cells turns into dry red patches that are sometimes painful. Psoriasis is a long-lasting, chronic type of disease having connection with body immune system. 

Major sign and symptoms of psoriasis include Red patches of skin covered with silvery scales, Small scaling spots, cracked skin that may bleed, Itching, burning or soreness, Thickened, pitted or ridged nails, Swollen and stiff joints.

There are five main types of psoriasis pustular, erythrodermic, plaque, guttate and inverse. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases.Plaque psoriasis is characterized by formation of red patches with white scales on top. Most commonly affected area are forearms, shins and scalp. Guttate psoriasis is characterized by shaped lesions. Pustular psoriasis presents with small non infectious blisters filled by pus or aqueous liquid.Inverse psoriasis creates red pateches in skin folds while erythrodermic psoriasis occurs when rashes cover large area of skin .Most commonly affected area are toenails and fingernails.This may causes discoloration of nails.

Otezla vs stelara psoriatic arthritis, side effects, cost, reviews, dosage

Otezla vs Stelara Psoriatic arthritis side effects, cost, reviews, dosage

Otezla vs stelara psoriatic arthritis, side effects, cost, reviews, dosage

Psoriatic arthritis(PsA) is a kind of arthritis that affects sometimes people, who develop psoriasis. Psoriatic arthritis is an advance form of arthritis characterized by red patches of skin topped with silvery scales. Major sign and symptoms of psoriatic arthritis include swelling around the joints, stiffness and difficulty in walking.

Psoriatic arthritis may affect any part of body for example your fingers, spine, knee or elbow joints. Up till now licensed treatments for psoriatic arthritis are corticosteroids based therapy, tumor necrosis factor blockers, interleukin-12 and interleukin-23 inhibitors.

Otezla psoriatic arthritis treatment

The U.S. Food and Drug Administration has been approved Otezla (apremilast) for the treatment of psoriatic arthritis(PsA) on  March 21, 2014. Otezla (apremilast) is categorized as new medication for psoriatic arthritis treatment. Otezla is active through oral rout.

It’s main mechanism of action includes inhibition of enzyme phosphodiesterase 4 (PDE4). Otezla (apremilast) rapidly inhibits PDE-4 and blocks the production of tumor necrotic factor alpha(TNF-alpha) from human rheumatoid synovial cells. Otezla (apremilast) also exerts anti  inflammatory activity.

Otezla psoriatic arthritis treatment cost

Otezla is available in tablet dosage form. It has potency of 30 mg. It is expensive item and a typical fill can cost $2,274 or more for 60 tablets of Otezla 30 mg.

Otezla psoriatic arthritis treatment side effects

Otezla (apremilast) has side effects ranges from moderate to severe. Moderate side effects include headache, nausea, vomiting, stuffy nose, cold, sore throat, sneezing. Severe side effects include thoughts of suicide or hurting yourself, mood changes, acute episodes of depression and unexplained weight loss.

Otezla psoriatic arthritis treatment dosage

Otezla (apremilast) dosage is advised only for adults.It is not recommended for children. Recommended dosage of otezla is 10 mg in morning time for 3 consecutive days and then increase the dose up to 20 mg for next 3 days, after that titrate the dose up to 30 mg per day or twice a day for 1-2 weeks.

Otezla psoriatic arthritis treatment reviews

According to various clinical studies and data obtained from The U.S. Food and Drug Administration the safety and effectiveness  of Otezla, an inhibitor of phosphodieasterase-4 (PDE-4), were evaluated in three clinical trials involving 1493 patients  with active psoriatic arthritis. Patients treated with Otezla showed improvement in signs and symptoms of psoriatic arthritis, including tender and swollen joints and physical function, compared to placebo.

Stelara psoriatic arthritis treatment

The U.S. Food and Drug Administration has been approved Stelara for the treatment of psoriatic arthritis(PsA) on September 25, 2009.Stelara is a brand name registered by CENTM ORTHO BIOTECH INCcontain and its active ingredient is Ustekinumab.

Stelara(Ustekinumab) is a specific monoclonal antibody that works against interleukin 12 and interleukin 23.These types of interleukins are naturally occurring proteins that are part of immune system and are involved in immune mediated inflammatory disorders.

Stelara psoriatic arthritis treatment cost

It an expensive item that can cost about $8,362 or more for 1 syringe (0.5 ml) of Stelara 45 mg/0.5 ml, while a typical fill can
cost about $16,716 or more for 1 syringe (1 ml) of Stelara 90 mg/ml.

Stelara psoriatic arthritis treatment side effects

According to various clinical studies and data provided by Centocor most common side effects are headache, allergic reaction, nausea, vomiting, seizures,  Nasopharyngitis, Upper respiratory tract infection, Dizziness and depression.

Stelara psoriatic arthritis treatment dosage

Sterala is available in parentral form with two types of potency.One is 0.5 ml of 45 mg/0.5 ml and other is 1 ml of 90 mg/ml. Recommend dose of sterala injection is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.

Stelara psoriatic arthritis treatment reviews

According to clinical trials and data recovered from Centocor drug shows more efficacy in patients suffering from moderate to severe plaque psoriasis or advance type of psoriasis.The drug is well tolerated by various patients in phase III clinical trials.

One comment

  1. It’s hard to say

Leave a Reply

Your email address will not be published. Required fields are marked *